Adropin as a potential marker of enzyme-positive acute coronary syndrome

Aydin S., Eren M. N., Yilmaz M., Kalayci M., Yardim M., Alatas O. D., ...More

CARDIOVASCULAR JOURNAL OF AFRICA, vol.28, no.1, pp.40-47, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.5830/cvja-2016-055
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.40-47
  • Van Yüzüncü Yıl University Affiliated: No


Aim: Enzyme-positive acute coronary syndrome (EPACS) can cause injury to or death of the heart muscle owing to prolonged ischaemia. Recent research has indicated that in addition to liver and brain cells, cardiomyocytes also produce adropin. We hypothesised that adropin is released into the bloodstream during myocardial injury caused by acute coronary syndrome (ACS), so serum and saliva levels rise as the myocytes die. Therefore, it could be useful to investigate how ACS affects the timing and significance of adropin release in human subjects.